Trial
NCT02263508
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Amgen
Collaborators
Merck Sharp & Dohme LLC
Condition
Melanoma
Intervention
Talimogene Laherparepvec
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-14